Journal article icon

Journal article

The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy.

Abstract:

Anti-tumour necrosis factor antagonists have appreciably improved patient outcomes in Crohn's disease, shifting the goals of treatment from control of symptoms to clinical remission (Crohn's disease activity index <150) combined with mucosal healing - the new concept of 'deep remission'. Achieving deep remission brings clinically meaningful benefits, including reduced hospitalization and reduced need for surgery. Aspects such as the dose, timing and intensification of anti-tumour necrosis ...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
Journal:
Journal of Crohn's and colitis More from this journal
Volume:
6 Suppl 2
Pages:
S250-S259
Publication date:
2012-02-01
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Language:
English
Keywords:
Pubs id:
pubs:321713
UUID:
uuid:cda4b293-06fb-4fb2-a6f3-a1cc8917cb17
Local pid:
pubs:321713
Source identifiers:
321713
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP